PANCREATIC ADENOSQUAMOUS CARCINOMA
Clinical trials for PANCREATIC ADENOSQUAMOUS CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC ADENOSQUAMOUS CARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC ADENOSQUAMOUS CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill plus chemo takes on deadly pancreatic cancer in huge trial
Disease control Recruiting nowThis phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Last-Resort drug access opens for advanced pancreatic cancer patients
Disease control AVAILABLEThis program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC